Related Experiment Videos
Malignant hyperthermia: a review of published cases
1Glaxo Research Institute, Research Triangle Park, North Carolina 27709.
Anesthesia and Analgesia
|August 1, 1993
Summary
Malignant hyperthermia (MH), a rare anesthesia complication, disproportionately affects pediatric males. While congenital defects and certain surgeries increase risk, improved awareness and dantrolene therapy have reduced MH mortality rates.
Area of Science:
- Anesthesiology
- Pharmacology
- Medical Genetics
Background:
- Malignant hyperthermia (MH) is a severe, unpredictable reaction to certain anesthetic agents.
- Understanding MH epidemiology is crucial for patient safety and risk management.
Purpose of the Study:
- To investigate the global epidemiology of Malignant hyperthermia (MH).
- To identify associations between MH, specific drugs, and patient demographics.
- To analyze trends in MH-associated mortality rates.
Main Methods:
- Analysis of 503 reported cases of Malignant hyperthermia (MH).
- Comparison of MH patient demographics with the general surgical population.
- Examination of factors influencing MH incidence and outcomes, including pre-existing conditions and family history.
Main Results:
- Pediatric (52.1%) and male (65.8%) patients were overrepresented in MH cases.
- Congenital defects and musculoskeletal surgeries showed clear associations with MH.
- Absence of a positive family history (75.9%) and prior uneventful anesthesia (20.9%) were common.
- Case fatality rates declined to 10% since 1985.
Conclusions:
- Dantrolene therapy, increased vigilance, and community awareness have independently contributed to reduced MH mortality.
- MH epidemiology reveals specific demographic and clinical risk factors.
- Continued research and awareness are vital for managing Malignant hyperthermia effectively.